Pharmaceutical composition for intraarticular delivery
The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
1. A mixture for intraarticular delivery of a therapeutic agent, the mixture comprising:
a first phospholipid, a second phospholipid, and cholesterol, wherein the first phospholipid is selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC), soy phosphatidylcholine (SPC), and egg phosphatidylcholine (EPC), and the second phospholipid is polyethyleneglycol distearoylphosphatidylethanolamine (PEG-DSPE) or dipalmitoylphosphatidylglycerol (DOPG); and
wherein the cholesterol is at a mole percent of about 10 to about 33 based on the total amount of the first phospholipid, the second phospholipid and cholesterol.
2. The mixture of claim 1 , wherein the second phospholipid is DOPG at a mole percent ratio about 3 to 37.5 based on the total amount of the first phospholipid, the second phospholipid and cholesterol.
3. The mixture of claim 1 , wherein the first phospholipid is DOPC and the second phospholipid is DOPG.
4. The mixture of claim 3 , wherein the mole percent of DOPC:DOPG:cholesterol of the liposome is about 29.5 to 90:3 to 37.5:10 to 33.
5. The mixture of claim 3 , wherein the mole percent of DOPC:DOPG:cholesterol of the liposome is about 56.25 to 72.5:7.5 to 18.75:20 to 25.
6. A method for delivering a therapeutic agent by the mixture of claim 4 to a subject suffering from arthritis, which comprises
providing a composition comprising:
the mixture of claim 1 and the therapeutic agent; and
intraarticularly administrating the composition to a subject suffering from arthritis.
7. The method of claim 6 , wherein the therapeutic agent comprises a water soluble steroid solution comprising an effective amount of a water soluble steroid or a pharmaceutically acceptable salt thereof.
8. The method of claim 7 , wherein the water soluble steroid is dexamethasone sodium phosphate.
9. The method of claim 7 , wherein the water soluble steroid solution has a potency equivalent to about a 2 mg dose to about a 8 mg dose of dexamethasone.
10. The method of claim 6 , wherein the therapeutic agent comprises a nonsteroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof.
11. The method of claim 10 , wherein the nonsteroidal anti-inflammatory drug is indomethacin.
12. The method of claim 10 , wherein the pharmaceutically acceptable salt of the nonsteroidal anti-inflammatory drug is indomethacin sodium.
13. The method of claim 10 , wherein the dose of the nonsteroidal anti-inflammatory drug or its pharmaceutically acceptable salt is 4.65 to 5 mg/ml.
14. The method of claim 6 , wherein the therapeutic agent comprises a disease-modifying anti-rheumatic drug (DMARD).
15. The method of claim 14 , wherein the DMARD comprises a TNF-α antagonist.
16. The method of claim 15 , wherein the TNF-α antagonist is etanercept.
17. The method of claim 16 , wherein the dose of etanercept is 42.8 mg/ml to 50 mg/ml.
18. The method of claim 15 , wherein the TNF-α antagonist is adalimumab.
19. The method of claim 14 , wherein the DMARD comprises methotrexate or a pharmaceutically acceptable salt thereof.
20. The method of claim 19 , wherein the pharmaceutically acceptable salt of methotrexate is methotrexate sodium.
21. The method of claim 19 , wherein the dose of methotrexate or its pharmaceutically acceptable salt is 2.3 to 2.5 mg/ml.